Name: VX-702
Brand: Selleck Chemicals
SKU: S6005
Rating: 5 (32 reviews)

CAS No. 745833-23-2

Selleck's VX-702 has been cited by 32 publications

Purity & Quality Control

Choose Selective p38 MAPK Inhibitors

Related Compound Libraries

Other p38 MAPK Products

Download Inhibitor Catalog

p38 MAPK Signaling Pathway Map

Biological Activity

Description

VX-702 is a highly selective inhibitor of p38α MAPK, 14-fold higher potency against the p38α versus p38β. Phase 2.

Features

Highly selective, orally active inhibitor of p38 MAPK.

Targets

p38α ^[1]
(Cell-free assay)

4 nM-20 nM

In vitro

Pre-incubation of platelets with VX-702 (1 μM) completely or partially inhibits p38 activation (IC50 4 to 20 nM) induced by platelet agonists including thrombin, SFLLRN, AYPGKF, U46619 and collagen. VX-702 shows no effect on platelet aggregation induced by any of the p38 MAPK agonists in the presence or absence of anti-platelet therapies. ^[1] VX-702 inhibits the production of IL-6, IL-1β and TNFα (IC50 = 59, 122 and 99 ng/mL, respectively) in a dose-dependent manner. ^[2]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID

HOP-62 cell	NIS4WpdIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	NVey[GxbUW6qaXLpeIlwdiCxZjDoeY1idiCKT2CtOlIh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjBzNUSzJO69VQ>?	MlzKV2FPT0WU
human NCI-H720 cell	M2fx[mdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	NF\jTXBKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3IO\|IxKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC5yMU[4NkDPxE1?	M{jQN3NCVkeHUh?=
JVM-2 cell	M1z2Wmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	NGDy[GRKdmirYnn0bY9vKG:oIHj1cYFvKEqYTT2yJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4xQDNizszN	MXrTRW5ITVJ?
human NCI-H69 cell	M4nBPWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	M1vkdWlvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLVi2PUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvODl7NEGg{txO	M{nnWXNCVkeHUh?=
human BV-173 cell	NIXXPHhIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	MlvyTY5pcWKrdHnvckBw\iCqdX3hckBDXi1zN{OgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlEyOzh4IN88US=>	NYeyW2d7W0GQR1XS
human KU812 cell	NF;ifZZIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	M3XyWmlvcGmkaYTpc44hd2ZiaIXtZY4hU1V6MUKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlEzPDh6IN88US=>	MYfTRW5ITVJ?
human DU-145 cell	NUXRbGo6T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	MnvQTY5pcWKrdHnvckBw\iCqdX3hckBFXS1zNEWgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlE1PTV2IN88US=>	NEWxdGpUSU6JRWK=
KARPAS-45 cell	MW\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	NXv1W5NZUW6qaXLpeIlwdiCxZjDoeY1idiCNQWLQRXMuPDViY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLkG0PFI3KM7:TR?=	M2n4bnNCVkeHUh?=
human AGS cell	MUjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	NVTJVnZpUW6qaXLpeIlwdiCxZjDoeY1idiCDR2OgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlE2OjVzIN88US=>	MUnTRW5ITVJ?
human MOLT-13 cell	MVXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	M1PnVmlvcGmkaYTpc44hd2ZiaIXtZY4hVU:OVD2xN{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOTV7OEGg{txO	NX;LVWZqW0GQR1XS
human NCI-H209 cell	MmPUS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	M2W2e2lvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLViyNFkh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjF5NUig{txO	NULvZm9oW0GQR1XS
human CTV-1 cell	NGfDUm9Iem:5dHigbY5pcWKrdHnvckBie3OjeR?=	NIPhSWxKdmirYnn0bY9vKG:oIHj1cYFvKEOWVj2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4yQDN6OTFOwG0>	M{TobXNCVkeHUh?=
LU-139 cell	Mly0S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	NYX4d3V6UW6qaXLpeIlwdiCxZjDoeY1idiCOVT2xN\|kh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjF7NEO1JO69VQ>?	MmTUV2FPT0WU
ML-2 cell	NXnkUZlNT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	NXPhXYUxUW6qaXLpeIlwdiCxZjDoeY1idiCPTD2yJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4zOjZ4MTFOwG0>	NEHaeJJUSU6JRWK=
human K5 cell	NXLReHR1T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	NGPleWFKdmirYnn0bY9vKG:oIHj1cYFvKEt3IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;MD6yNlkyPyEQvF2=	NFWxeldUSU6JRWK=
human SBC-1 cell	NWHXdXQ1T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	NUDSfIg3UW6qaXLpeIlwdiCxZjDoeY1idiCVQlOtNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOjN4MjFOwG0>	MkPXV2FPT0WU
human COR-L88 cell	NGLKcZpIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	M3G5UGlvcGmkaYTpc44hd2ZiaIXtZY4hS0:ULVy4PEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOzN2ODFOwG0>	NYjT[GZ5W0GQR1XS
human KY821 cell	MWjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	M1[yU2lvcGmkaYTpc44hd2ZiaIXtZY4hU1l6MkGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlM6PjB\|IN88US=>	NHXQcYVUSU6JRWK=
human HCC2218 cell	M4nyXGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	NFi4eWtKdmirYnn0bY9vKG:oIHj1cYFvKEiFQ{KyNVgh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjR7N{K4JO69VQ>?	MnPaV2FPT0WU
human ECC10 cell	MXHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	NWjGS2FqUW6qaXLpeIlwdiCxZjDoeY1idiCHQ1OxNEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvPjV\|OEmg{txO	MV3TRW5ITVJ?
human EW-3 cell	NVKzOpV4T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	MlTOTY5pcWKrdHnvckBw\iCqdX3hckBGXy1\|IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;MD62OlYyOSEQvF2=	M1\IWHNCVkeHUh?=
human EW-18 cell	M3HZO2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7	Ml;QTY5pcWKrdHnvckBw\iCqdX3hckBGXy1zODDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUCuO\|Q3PzlizszN	NXTzTXF4W0GQR1XS
human UACC-257 cell	NGWyXVlIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	NYLFenFGUW6qaXLpeIlwdiCxZjDoeY1idiCXQVPDMVI2PyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxRTFwMkCzNlYh\|ryP	MnKyV2FPT0WU
human G-361 cell	NI\SSpVIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	MlnPTY5pcWKrdHnvckBw\iCqdX3hckBINTN4MTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUGuOFk2OTlizszN	NVq1RXluW0GQR1XS
human HMV-II cell	NITpOpVIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	NGLVSoVKdmirYnn0bY9vKG:oIHj1cYFvKEiPVj3JTUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEvPzdzOESg{txO	MnPmV2FPT0WU
human DEL cell	NXHk[YxKT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	NVnUT\|BSUW6qaXLpeIlwdiCxZjDoeY1idiCGRVygZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yMlIxPzB2IN88US=>	M{XPN3NCVkeHUh?=
human IGROV-1 cell	NEmyUlBIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	NImxc\|lKdmirYnn0bY9vKG:oIHj1cYFvKEmJUl;WMVEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0zNjR\|MUi4JO69VQ>?	MoXZV2FPT0WU
human SK-OV-3 cell	MnHCS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	NI\SeoRKdmirYnn0bY9vKG:oIHj1cYFvKFONLV;WMVMh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0zNjZzNkm3JO69VQ>?	M4jIfHNCVkeHUh?=
human LAMA-84 cell	NWTUemQ2T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	NVPCOoxVUW6qaXLpeIlwdiCxZjDoeY1idiCOQV3BMVg1KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Oi55MUK4OEDPxE1?	M1zsVnNCVkeHUh?=
human NCI-H510A cell	NIX4R4dIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	MVjJcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KNUGwRUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVIvQTJ3Mk[g{txO	M1\0W3NCVkeHUh?=
human CP66-MEL cell	NFrqR\|BIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	M3jP[WlvcGmkaYTpc44hd2ZiaIXtZY4hS1B4Nj3NSWwh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0zNjl\|NUW5JO69VQ>?	M4TlcnNCVkeHUh?=
human HAL-01 cell	NXzVUWExT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	NVr1dnNEUW6qaXLpeIlwdiCxZjDoeY1idiCKQVytNFEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0{NjJ5OUG4JO69VQ>?	MmDZV2FPT0WU
human RS4-11 cell	NXPvRoRzT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	MWPJcohq[mm2aX;uJI9nKGi3bXHuJHJUPC1zMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUOuO\|A2PzNizszN	MYHTRW5ITVJ?
human RPMI-8226 cell	M3fqXWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	MYfJcohq[mm2aX;uJI9nKGi3bXHuJHJRVUlvOEKyOkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVMvQDJ\|N{[g{txO	MYHTRW5ITVJ?
human NCI-H82 cell	MkX1S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	MljjTY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSEiyJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9N{45QTNyNTFOwG0>	MVrTRW5ITVJ?
human NY cells	MkHJS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	NUXLNIxXUW6qaXLpeIlwdiCxZjDoeY1idiCQWTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUSuNlc3OzdizszN	NGX4XplUSU6JRWK=
human MDA-MB-361 cell	MV3Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	NVm4WJBJUW6qaXLpeIlwdiCxZjDoeY1idiCPRFGtUWIuOzZzIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;ND60N\|E2QCEQvF2=	Ml22V2FPT0WU
human MOLT-4 cell	Ml;4S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	NUPtXFFRUW6qaXLpeIlwdiCxZjDoeY1idiCPT1zUMVQh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF01Njl7MUmzJO69VQ>?	Ml;UV2FPT0WU
human DU-4475 cell	MYnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	M2e5OGlvcGmkaYTpc44hd2ZiaIXtZY4hTFVvNES3OUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVUvODV3NkWg{txO	MnLKV2FPT0WU
human ESS-1 cell	MVTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	NIHSfWVKdmirYnn0bY9vKG:oIHj1cYFvKEWVUz2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OU4zQTF5OTFOwG0>	M4jDSHNCVkeHUh?=
human NCI-H1299 cell	NX;pe3I2T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	NV[yPGZ4UW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFEzQTliY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD13LkWzNFM{KM7:TR?=	NVXYWWxTW0GQR1XS
human COLO-684 cell	NUTMVWo2T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	MVrJcohq[mm2aX;uJI9nKGi3bXHuJGNQVE9vNki0JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OU42QDF4NTFOwG0>	NYXOR5AxW0GQR1XS
human MV-4-11 cell	MnvTS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	M2XKcWlvcGmkaYTpc44hd2ZiaIXtZY4hVVZvND2xNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVUvPzFzOUmg{txO	MXPTRW5ITVJ?
human D-542MG cell	M2mzfWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	MUjJcohq[mm2aX;uJI9nKGi3bXHuJGQuPTR{TVegZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME22MlM6Ojd{IN88US=>	M1zzO3NCVkeHUh?=
human A4-Fuk cell	NIT0eXNIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	MWXJcohq[mm2aX;uJI9nKGi3bXHuJGE1NU[3azDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPU[uOFM3PjJizszN	M4TkbHNCVkeHUh?=
human HL-60 cell	MoXYS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	NVvTUoViUW6qaXLpeIlwdiCxZjDoeY1idiCKTD22NEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVcvPTJ{MUKg{txO	NYThUVRDW0GQR1XS
human NCI-H526 cell	M3P2WGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	NGD0R3BKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3IOVI3KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Py53OUiwNUDPxE1?	NYPRd5VXW0GQR1XS
human L-363 cell	M1fpfmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	MV7Jcohq[mm2aX;uJI9nKGi3bXHuJGwuOzZ\|IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;Nz63PVI2OiEQvF2=	MUnTRW5ITVJ?
human A388 cell	Mnr5S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	M2XsZmlvcGmkaYTpc44hd2ZiaIXtZY4hSTN6ODDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUeuPFA{QDRizszN	M4XMS3NCVkeHUh?=
human MS-1	NVTnPIhpT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	MV7Jcohq[mm2aX;uJI9nKGi3bXHuJG1UNTFiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD15LkizOFY2KM7:TR?=	NX3qbGY4W0GQR1XS
human JAR cell	MUfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	MYPJcohq[mm2aX;uJI9nKGi3bXHuJGpCWiClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxRTdwOES5NlMh\|ryP	NXX5SVRlW0GQR1XS
human TI-73 cell	MmPNS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	MVHJcohq[mm2aX;uJI9nKGi3bXHuJHRKNTd\|IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;OD6wOlIzKM7:TR?=	MVTTRW5ITVJ?
human CTB-1 cell	M4XlUmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	Mn:xTY5pcWKrdHnvckBw\iCqdX3hckBEXEJvMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUiuNVc5OjVizszN	MoLyV2FPT0WU
human SK-NEP-1 cell	MmDkS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	MWHJcohq[mm2aX;uJI9nKGi3bXHuJHNMNU6HUD2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NVEvOzB\|ODFOwG0>	NXW0T3dEW0GQR1XS
human HT-29 cell	MXHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	NFrwcGZKdmirYnn0bY9vKG:oIHj1cYFvKEiWLUK5JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NVMvQTFzMTFOwG0>	M{K1d3NCVkeHUh?=
human NCI-H1092 cell	NH\nb\|ZIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	MkLNTY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSEGwPVIh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0yPC5\|MUig{txO	MkHzV2FPT0WU
human KMOE-2 cell	NUizfndqT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	NEfVOJNKdmirYnn0bY9vKG:oIHj1cYFvKEuPT1WtNkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVE1NjZzN{ig{txO	NXHLW4tKW0GQR1XS
human EM-2 cell	NV\zVFVzT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	NFW1dpdKdmirYnn0bY9vKG:oIHj1cYFvKEWPLUKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xOU4zQDRzIN88US=>	NHzNTWpUSU6JRWK=
human RT-112 cell	M1rv[Gdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	M1LldmlvcGmkaYTpc44hd2ZiaIXtZY4hWlRvMUGyJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NVUvOzl6NDFOwG0>	MYnTRW5ITVJ?
human DB cell	MXzHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	MVHJcohq[mm2aX;uJI9nKGi3bXHuJGRDKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OTVwOEWxN{DPxE1?	Mki5V2FPT0WU
human NCI-H1770 cell	MlX5S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	NVjHbGRVUW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFE4PzBiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeR?=	NXvFNJR{W0GQR1XS
human CAL-54 cell	Mn[2S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	NH;qXINKdmirYnn0bY9vKG:oIHj1cYFvKEODTD21OEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVE3Njd\|IN88US=>	NX7FOG1TW0GQR1XS
human NB14 cell	MWDHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	MmjyTY5pcWKrdHnvckBw\iCqdX3hckBPSjF2IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;MUeuOlM6PSEQvF2=	NXq5cZdWW0GQR1XS
human RPMI-7951 cell	NFm1TG9Iem:5dHigbY5pcWKrdHnvckBie3OjeR?=	NWTtXJpEUW6qaXLpeIlwdiCxZjDoeY1idiCUUF3JMVc6PTFiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1zOT6xO\|g{KM7:TR?=	Mn;LV2FPT0WU
human T47D cell	NV62fYpXT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	Mnr4TY5pcWKrdHnvckBw\iCqdX3hckBVPDeGIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;MkGuNlI1OyEQvF2=	MUjTRW5ITVJ?
human A549 cell	MnPPS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	NHSwfIxKdmirYnn0bY9vKG:oIHj1cYFvKEF3NEmgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yNU4zQDFzIN88US=>	MWHTRW5ITVJ?
human A2780 cell	MVrHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	NV71V3FEUW6qaXLpeIlwdiCxZjDoeY1idiCDMke4NEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVIyNjh{MkWg{txO	M1[3XnNCVkeHUh?=
human SK-MEL-24 cell	MUXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	NEjEOoVKdmirYnn0bY9vKG:oIHj1cYFvKFONLV3FUE0zPCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxRTN\|LkCzNVEh\|ryP	MU\TRW5ITVJ?

Click to View More Cell Line Experimental Data

In vivo

The half-life of VX-702 is 16 to 20 hours, with a median clearance of 3.75 L/h and a volume of distribution of 73 L/kg. Both AUC and C_max values are dose proportional for VX-702, which is predominantly cleared renally. ^[2] VX-702 (at a dose of 0.1 mg/kg twice daily) has an equivalent effect as that of methotrexate (0.1 mg/kg). In addition, VX-702 (5 mg/kg twice daily) also has an equivalent effect as prednisolone (10 mg/kg once daily), as measured by percentage inhibition of wrist joint erosion and inflammation score. ^[3] VX-702 selectively inhibits activation of p38 MAPK after ischemia with no effects on ERKs and JNKs. The MI/AAR ratio is significantly reduced in the 50 mg/kg group compared with the 5 mg/kg and vehicle groups.^[4]

Protocol (from reference)

References

[4] Bhattacharya K, et al. Circulation, 2003, 108(17), 882.

+ Expand

Solubility (25°C)

In vitro	DMSO	81 mg/mL (200.34 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order (Data is from Selleck tests instead of citations): 5% DMSO+40% PEG 300+5% Tween 80+50% ddH2O For best results, use promptly after mixing. Click to purchase: PEG300 Tween 80	4 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight	404.3
Formula	C₁₉H₁₂F₄N₄O₂
CAS No.	745833-23-2
Storage	3 years	-20°C	powder
Storage	2 years	-80°C	in solvent
Smiles	C1=CC(=C(C(=C1)F)N(C2=NC(=C(C=C2)C(=O)N)C3=C(C=C(C=C3)F)F)C(=O)N)F

Download VX-702 SDF

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg Average weight of animals: g Dosing volume per animal:μL Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO + % + % Tween 80 + % ddH₂O

%DMSO+ %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Dilution Calculator Molecular Weight Calculator

Clinical Trial Information

NCT Number	Recruitment	Interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT00395577	Completed	Drug: VX-702	Rheumatoid Arthritis	Vertex Pharmaceuticals Incorporated	November 2006	Phase 2

(data from https://clinicaltrials.gov, updated on 2022-01-17)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):